Are we having fun yet?

Are we having fun yet?

Yes rarely a few days go by without the MannKind (NASDAQ:MNKD) and Sanofi (NYSE:SNY) zealots doing their best to defend their convoluted positions. As has become standard operating procedure for the MannKind zealots they will use any piece of data, real or imagined, to support the stock. This is not all the unusual for these pump and dumpers. Let’s be honest here folks it’s way too early to know how Afrezza is doing but this won’t stop the hype and likely will only enhance the hype.

Think about this for a moment with no hard evidence on how Afrezza is really doing supporters and detractors of MannKind can speculate and pontificate to their hearts content. As we have noted in the past never let facts get in the way of a good fantasy. This situation actually reminds Diabetic Investor of how baseball fans here in Chicago are speculating about their teams. Yes for the first time in a long time on paper both the Cubs and White Sox look like contenders. Excite abounds here in the Windy City as with both teams in spring training hope springs eternal after all at the moment both teams are in first place. Never mind that not a single game that actually matters has been played, what the heck better to enjoy the hype.

This is exactly what’s going on with MannKind and Afrezza sales the main difference is that real games are now underway, we just don’t know the score of the game. Complicating matters for MannKind is just what Brandicourt will do with Afrezza. Will he look at these very early numbers and conclude it’s best to cut ties now before Afrezza turns into a sinkhole draining Sanofi resources. Or will he continue to throw good money into a bad situation. No one, not even Brandicourt we suspect, knows what he’ll do.

Yet Afrezza is not the only dish on Brandicourt’s very full plate. Now that Toujeo has been approved he must repair relations with  a demoralized sales force and do whatever’s necessary to insure that Toujeo is not assigned to formulary purgatory. He knows that payors will be relentless in their attempt squeeze Sanofi as like everyone else they know that Lantus is going off patent and Sanofi is not negotiating from a strong position.

What amuses Diabetic Investor the most is how these zealots who know next to nothing about diabetes or the diabetes market will ignore history and believe that just because there are others who support their position they must be right. That since a handful of patients have expressed an interest in Afrezza that all patients are interested in using the drug. They speak to a few select physicians who are prescribing Afrezza and believe all physicians will prescribe it.

Diabetic Investor fully acknowledges it’s possible we are dead wrong about Afrezza and Toujeo. That Sanofi is a leopard that has changed its spots, that in spite of all the evidence to the contrary that they will get it right with Afrezza and Toujeo. This is after all the wacky world of diabetes where anything can and usually does happen. Yet given Sanofi’s history with previous products not named Lantus – Apidra and the iBGStar quickly come to mind – we are very comfortable with our position.

But we would like to say thank you to the many zealots as not only have they provided some great copy but they have provided some solid belly laughs while reading their posts. We’re not sure how much fun they are having but we’re having a blast – thanks.